Form 8-K - Current report:
SEC Accession No. 0001193125-25-162939
Filing Date
2025-07-23
Accepted
2025-07-23 08:00:40
Documents
13
Period of Report
2025-07-22
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d30630d8k.htm   iXBRL 8-K 27529
2 EX-3.1 d30630dex31.htm EX-3.1 9849
  Complete submission text file 0001193125-25-162939.txt   155014

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrca-20250722.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrca-20250722_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrca-20250722_pre.xml EX-101.PRE 11262
15 EXTRACTED XBRL INSTANCE DOCUMENT d30630d8k_htm.xml XML 3618
Mailing Address 10 NORTH HIGH STREET SUITE 200 WEST CHESTER PA 19380
Business Address 10 NORTH HIGH STREET SUITE 200 WEST CHESTER PA 19380 484-453-3300
Verrica Pharmaceuticals Inc. (Filer) CIK: 0001660334 (see all company filings)

EIN.: 463137900 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38529 | Film No.: 251141640
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)